Biotechnology

Halozyme Therap

Halozyme Therap released FY2026 Q1 earnings on May 11 After-Market EST, actual revenue USD 376.71 M (forecast USD 359.05 M), actual EPS USD 1.22 (forecast USD 1.2725)

Alozime Medical Exceeds Revenue Expectations in Q1 2026

Halozyme Therap to Release FY2026 Q1 Earnings on May 11 After-Market EST, Forecast Revenue USD 359.05 M, EPS USD 1.2725

Halozyme Therapeutics released FY2025 Q4 earnings on February 17 Pre-Market (EST), actual revenue USD 451.77 M (forecast USD 446.14 M), actual EPS USD -1.2032 (forecast USD 1.97)

Halozyme Therap released FY2025 annual earnings on February 17 Pre-Market EST, actual revenue USD 1.397 B (forecast USD 1.394 B), actual EPS USD 2.56 (forecast USD 5.636)

Aolozime Medical Raises 2026 Financial Guidance and Advances Strategic Growth Roadmap

Halozyme Therap released FY2025 9 Months earnings on November 3 After-Market EST, actual revenue USD 944.84 M, actual EPS USD 3.69

Halozyme Therap released FY2025 Q3 earnings on November 3 After-Market EST, forecast revenue USD 339.1M, forecast EPS USD 1.3875

Halozyme Therap to release FY2025 Q3 earnings on November 3 After-Market EST, forecast revenue USD 338.95 M, EPS USD 1.3875

Hedge Fund Recommends Halozyme Therapeutics as a Cheap Biotech Stock

Halozyme Therap released FY2025 Q2 earnings on August 5 After-Market (EST), actual revenue USD 325.72 M (forecast USD 285.92 M), actual EPS USD 1.33 (forecast USD 1.035)

Halozyme Therap released FY2025 Semi-Annual earnings on August 5 After-Market EST, actual revenue USD 590.58 M, actual EPS USD 2.26

Halozyme Therap to Release FY2025 Q2 Earnings on August 5 After-Market (EST), Forecast Revenue USD 285.92 M, EPS USD 1.035

Nasdaq Biotech Index Plummets

Halozyme Therap released FY2025 Q1 earnings on May 6 After-Market EST, actual revenue USD 264.86 M (forecast USD 230.18 M), actual EPS USD 0.93 (forecast USD 0.6175)

Auromedics Reports Q1 Pre-Tax Profit of $143.828 Million

Halozyme Therap to release FY2025 Q1 earnings on May 6 After-Market EST, forecast revenue USD 230.18 M, EPS USD 0.6175

Halozyme Therapeutics released FY2024 Q4 earnings on February 18 After-Market (EST), actual revenue $298.01M (forecast $285.74M), actual EPS $1.0617 (forecast $1.01)

Halozyme Therapeutics released FY2024 Annual Earnings on February 18 After-Market (EST), actual revenue $1.015 B (forecast $1.003 B), actual EPS $3.43 (forecast $3.3816)

Halozyme Therapeutics to Release FY2024 Q4 Earnings on February 18, After-Market EST; Forecasted Revenue: 285.74 M USD, EPS: 1.01 USD

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

HALO

LABU

SBIO

IBBQ

Halozyme Therapeutics CEO Helen Torley sold 20,000 shares at $71.75 each, totaling $1.435 million, reducing her ownership by 2.54%. Post-transaction, she holds 767,780 shares valued at approximately $55.1 million. This sale was part of a pre-arranged trading plan. Torley has made several other sales recently, with the stock's performance showing a 52-week range of $47.50 to $82.22. The company reported strong quarterly earnings, exceeding estimates, and has set FY 2026 EPS guidance between 7.750-8.250.

Market Beat

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

VanEck Biotech ETF

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Wells Fargo

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares

Morgan Stanley has lowered its price target for Halozyme Therapeutics (NASDAQ:HALO) from $96.00 to $93.00 while maintaining an "overweight" rating. This new target suggests a potential upside of 27.85% from the current price. Other firms have also adjusted their ratings, with Wells Fargo raising its target to $75.00 and HC Wainwright to $95.00. Halozyme's stock recently traded at $72.74, with a market cap of $8.62 billion and a P/E ratio of 29.22. The company reported strong quarterly earnings, exceeding estimates with a revenue increase of 42.2% year-over-year.

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Morgan Stanley Cuts Halozyme Therapeutics (NASDAQ:HALO) Price Target to $93.00

Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results and reaffirmed its FY2026 adjusted EPS and FY2026 sales guidance. Also, the company announced a new $1 billion share buyback program.

benzinga_article

Analyst Brendan Smith of TD Cowen has reiterated a Buy rating on Halozyme, maintaining a price target of $96. He cites strong growth driven by ENHANZE-based products and a new $1B share repurchase authorization as indicators of management's confidence. Smith believes the stock's growth potential is underappreciated, supported by robust first-quarter results and a long runway for future ENHANZE launches. H.C. Wainwright also supports this view with a Buy rating and a $95 price target.

Tip Ranks

Codexi

Repligen

Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target

Halozyme Therapeutics (NASDAQ:HALO) has updated its FY 2026 earnings guidance, projecting EPS between 7.750-8.250, slightly below the consensus estimate of 8.010. Revenue guidance is set at $1.7 billion-$1.8 billion, also below the consensus of $1.8 billion. The stock has seen various ratings from analysts, with a consensus rating of "Hold" and a target price of $79.11. Recent trading saw shares rise to $66.41, with a market cap of $7.87 billion. Insider trading activity included CEO Helen Torley selling 10,000 shares.

NASDAQ Composite Index

NASDAQ-100

Halozyme Therapeutics (NASDAQ:HALO) Releases FY 2026 Earnings Guidance

Earnings Watch

Halozyme Therap | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 376.71 M

Halozyme Therapeutics reported strong Q1 2026 results, with total revenue up 42% YOY to $377 million and a new $1 billion share repurchase program. The company reiterated its 2026 financial guidance, projecting total revenue of $1.710 - $1.810 billion and adjusted EBITDA of $1.125 - $1.205 billion. Recent collaborations with Vertex, GSK, and Oruka highlight the potential for new royalty revenue from ENHANZE products. The FDA approved VYVGART Hytrulo for generalized myasthenia gravis, expanding market opportunities. Halozyme expects ENHANZE royalty revenue to exceed $1 billion in 2026.

StockTitan

Vertex Pharma

Oruka Therapeutics

GlaxoSmithKline plc

Takeda Pharmaceutical Company

Takeda Pharmaceutical Co. Ltd.

Argenx

GSK plc Sponsored ADR

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE | HALO Stock News

ARKG

Halozyme Therapeutics will announce earnings results on Monday after market close. Last quarter, it reported revenues of $451.8 million, up 51.6% year on year, but missed EPS estimates. This quarter, revenue is expected to grow 34.1%. Analysts have reaffirmed estimates, indicating stability. Peers Novavax and Moderna have reported mixed results, with positive investor sentiment in the therapeutics segment. Halozyme's share price is down 5.3% recently, with an average analyst price target of $85.78 compared to its current price of $64.22.

Halozyme Therap(HALO.US)